European Registry on the Management of Helicobacter Pylori Infection
NCT02328131 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 10000
Last updated 2024-10-02
Summary
The great diversity of regimens and treatment lines, the different efficacy of these, mostly due to the increase in bacterial antibiotic resistance and regional differences, requires a continuous critical analysis of clinical practice, evaluating systematically the efficacy and safety of the different regimens and the cost-effectiveness of the different diagnostic-therapeutic strategies. This will help in the design of an efficient and optimized treatment that will reduce number of re-treatments, diagnostic tests and the appearance of associated pathologies such as peptic ulcers, gastrointestinal bleeding and, probably, gastric cancers. Therefore, the evaluation of real clinical practice using non-interventionist registries will help to improve the design and organization of European Consensus on the management of H. pylori infection, which is the best way to establish healthcare efficiency.
Primary aim
To obtain a database registering systematically over a year a large and representative sample of routine clinical practice of European gastroenterologists in order to produce descriptive studies of the management of H. pylori infection.
Secondary aims
1. To evaluate H. pylori infection consensus and clinical guidelines implementation in different countries.
2. To perform studies focused on epidemiology, efficacy and safety of the commonly used treatments to eradicate H. pylori.
3. To evaluate accessibility to healthcare technologies and drugs used in the management of H. pylori infection.
4. To allow the development of partial and specific analysis by the participating researchers after approval by the Registry's Scientific Committee
Methodology Non-interventionist prospective multicentre international registry promoted by the European Helicobacter Study Group. A renowned gastroenterologist from each country was selected as Local Coordinator (30 countries). They will in turn select up to ten gastroenterologists per country that will register the routine clinical practice consultations they receive over 10 years in an electronic Case Report Form (e-CRF). Variables retrieved will include clinical, diagnostic, treatment, eradication confirmation and outcome data. The database will allow researchers to perform specific subanalysis after approval by the Scientific Committee of the study.
Conditions
- H. Pylori Infection
Sponsors & Collaborators
-
Javier P. Gisbert
lead OTHER
Principal Investigators
-
Javier Pérez Gisbert, MD · Fundación de Investigación Biomédica - Hospital Universitario de La Princesa
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2013-06-30
- Primary Completion
- 2034-12-31
- Completion
- 2034-12-31
Countries
- Austria
- Belgium
- Bulgaria
- Croatia
- Czechia
- Denmark
- Estonia
- Finland
- France
- Germany
- Greece
- Hungary
- Ireland
- Italy
- Latvia
- Lithuania
- Netherlands
- Norway
- Poland
- Portugal
- Romania
- Russia
- Serbia
- Slovenia
- Spain
- Sweden
- Switzerland
- Turkey (Türkiye)
- Ukraine
- United Kingdom
Study Locations
More Related Trials
-
One Sequencing Find All for Helicobacter Pylori Infection
NCT03837990 ·Status: UNKNOWN
-
Helicobacter Pylori Prevalence in Southern Region of Romania
NCT05874960 ·Status: COMPLETED
-
Epidemiology of H. Pylori Transmission
NCT02740140 ·Status: COMPLETED
-
Epidemiology of Carbapenemase-producing Bacteria in a Swiss Tertiary Care Hospital
NCT04098133 ·Status: RECRUITING
-
Impact Of Bacterial Resistance On Healthcare Costs For Hospitalized Patients With Complicated Intra-Abdominal Infections
NCT00929643 ·Status: COMPLETED
-
The Role of Cathepsin X in Infection With the Helicobacter Pylori
NCT01137942 ·Status: UNKNOWN
-
Prevalence of Digestive Carriage of Integrons
NCT01985217 ·Status: COMPLETED
-
Phase 1a/b Study on Safety of IMX101 in H. Pylori-negative and H. Pylori-infected Healthy Volunteers
NCT03270800 ·Status: COMPLETED ·Phase: PHASE1
-
Prevalence of Enterobacteria With Decreased Susceptibility to Carbapenems in Eastern Inter- Region
NCT02803710 ·Status: UNKNOWN
-
Rectal Carriage of Carbapenemase Producing-Enterobacteriaceae on Admission to a French University Teaching Hospital
NCT05798351 ·Status: RECRUITING
-
Carbapenem-resistant Enterobacteriaceae: Prevalence, Risk Factors and Impact of the Use of the Phenotypic Algorithm for the Detection of Carbapenemases
NCT02127450 ·Status: COMPLETED
-
Transmission of ESBL-producing Enterobacteriaceae
NCT03465683 ·Status: RECRUITING
-
Microbiota Study in Liver Transplanted Patients
NCT03507140 ·Status: COMPLETED
-
Hepatitis E Infection : Emergence Mechanisms in North-Eastern France of Polymorphic Clinical Forms.
NCT03524014 ·Status: UNKNOWN
-
Study of the Impact of the Minimum Inhibitory Concentration and Susceptible Cut-off Points (CLSI, EUCAST, and Pharmacokinetics/Pharmacodynamics)in Prognosis of Bacteremia by Enterobacteriaceae
NCT02005159 ·Status: COMPLETED
-
Pancreatitis - Microbiome As Predictor of Severity
NCT04777812 ·Status: COMPLETED ·Phase: NA
-
Effect of Imipenem and Meropenem on the Digestive Microbiota and the Emergence and Carriage of Multidrug-resistant Bacteria
NCT05516433 ·Status: RECRUITING
-
Management of Infectious Endocarditis as Part of a Multidisciplinary Consensus Meeting
NCT03429153 ·Status: UNKNOWN
-
Bloodstream Infection Due to Multidrug-Resistant Organisms - Multicenter Study on Determinants of Clinical Outcomes
NCT03578835 ·Status: UNKNOWN
-
Developing Microbials to Fight Extended-spectrum Beta-lactamase (ESBL)-Producing Escherichia Coli
NCT04764500 ·Status: ACTIVE_NOT_RECRUITING
-
Carbapenem Antibiotic Therapy for VIM Carbapenemase-Producing Enterobacteriaceae Infections
NCT06185153 ·Status: RECRUITING
-
Concomitant Infection of Intestinal Parasites and Helicobacter Pylori
NCT05360940 ·Status: UNKNOWN
-
Emergence of Resistance in Intestinal Microflora During Carbapenem Treatments
NCT01703299 ·Status: COMPLETED
-
Impact of Beta-lactams on the Microbiota and Relative Fecal Abundance of Mulltidrug Resistant Bacteria
NCT03338738 ·Status: COMPLETED ·Phase: NA
-
Prevention of Carbapenemase-producing Enterobacteriaceae Epidemics: Evaluation of a Simplified Contact Screening Policy (CADECO)
NCT06839911 ·Status: ACTIVE_NOT_RECRUITING